13 State-of-the-art
Manufacturing sites

Our Operations

Our thirteen separate production plants have been designed to fully comply with the current regulations for Good Manufacturing Practice (GMP) of the European Union and the World Health Organization (WHO).

At the AZ factory we can produce and pack 1.5 billion tablets and 300 million capsules per year. Our injectables plant of cephalosporins is built online from the washing of the vials and sterilization units to the filling stage to rubber stoppering of the vials, capping, labeling and final packaging.

Our latest injectables manufacturing plant in Cyprus is for ampoules. It has a production and packing capacity of 40 million ampoules for injection per year. In our factory in the Netherlands we develop oral dosage forms. We also sell dossiers to third parties for registration in other EU and non-EU territories.

Our dry powder inhaler (DPI) facility Andi-Ventis is dedicated to the production of DPIs in a state-of-the-art facility. Here, we develop powders for inhalation used for the treatment of asthma in our own R&D department.

We manufacture oral cephalosporins as well as oral and injectable penicillin’s in separate manufacturing plants.

Our latest strategic investments are the new manufacturing plants in Vietnam, operating in full compliance with current regulations for Good Manufacturing Practice (GMP) of the European Union and the World Health Organization (WHO).

Medochemie (Far East) Ltd. has 3 manufacturing plants:

  • Oral facility (non-beta lactam) has started operating since May 2011, with a capacity of 2 billion tablets and 600 million capsules per year.
  • Cephalosporin’s Injectable facility has started operating since June 2017, with a capacity of 55 million vials per year.
  • Liquids & Semi-Solids facility has started operating since April 2018, with a capacity of 30 million bottles and 3 million tubes per year.

One manufacturing plant is under construction in Vietnam and will start the production of Penicillin’s injectable (powder for injection/infusion) in a state-of-the-art facility by the end of 2022.

Medochemie World

We develop, license, manufacture, market, and distribute branded generic and super-generic pharmaceutical products as well as our own patented brands.

Manufacturing Sites

Our thirteen separate production plants have been designed to fully comply with the current regulations for Good Manufacturing Practice of the European Union and the World Health Organization.

Quality Assurance

At Medochemie, we believe that it is our responsibility to determine and follow the most effective and efficient quality processes.